What is CytoSorbents Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. CytoSorbents's interest expense for the
three
months ended in Mar. 2024 was $ -0.01 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.10 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. CytoSorbents's Operating Income for the
three
months ended in Mar. 2024 was $ -4.93 Mil. CytoSorbents's Interest Expense for the
three
months ended in Mar. 2024 was $ -0.01 Mil.
CytoSorbents did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
CytoSorbents Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytoSorbents (NAS:CTSO) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
CytoSorbents's Interest Expense for the
three
months ended in Mar. 2024 was $-0.01 Mil. Its
Operating Income
for the
three
months ended in Mar. 2024 was $-4.93 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Mar. 2024 was $14.72 Mil.
CytoSorbents's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as
| CytoSorbents did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
CytoSorbents (CytoSorbents) Business Description
Traded in Other Exchanges
Address
305 College Road East, Princeton, NJ, USA, 08540
CytoSorbents Corp is involves in the treatment of life-threatening conditions in the intensive care (ICU) and cardiac surgery using blood purification via proprietary polymer adsorption technology. It has a number of products commercialized and in development based on this technology platform.
Executives
| Edward Raymond Jones |
director |
70 HOGAN LANE, AMBLER PA 19002 |
| Kathleen P. Bloch |
officer: Chief Financial Officer |
3 PERSHING COURT, NORTH BRUNSWICK NJ 08902 |
| Vincent Capponi |
officer: Chief Operating Officer |
MEDASORB TECHNOLOGIES, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852 |
| Phillip P. Chan |
director, officer: President and CEO |
1001 BRIGGS ROAD, SUITE 280, MOUNT LAUREL NJ 08054 |
| Efthymios Deliargyris |
officer: Chief Medical Officer |
C/O PLX PHARMA,INC.8285 EL RIO STREET, SUITE 210, HOUSTON TX 77054 |
| Jiny Kim |
director |
C/O CYTOSORBENTS CORPORATION, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852 |
| Alan D. Sobel |
director |
293 EISENHOWER PARKWAY, LIVINGSTON NJ 07039 |
| Michael G. Bator |
director |
C/O CYTOSORBENTS CORP., 7 DEER PARK DR., SUITE K, MONMOUTH JUNCTION NJ 08852 |
| Alex D'amico |
officer: Chief Financial Officer |
10 EAST PASSAIC AVENUE, UNIT C-2, NUTLEY NJ 07110 |
| Al Kraus |
director |
MEDASORB TECHNOLOGIES, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852 |
| Eric R. Mortensen |
officer: Chief Medical Officer |
C/O CYTOSORBENTS CORPORATION, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852 |
| Njtc Investment Fund, Lp |
10 percent owner |
1001 BRIGGS ROAD, SUITE 280, MOUNT LAUREL NJ 08054 |
| Robert Shipley |
10 percent owner |
9 NOBLE ROAD, NOGALES AZ 85621 |
| Ronald Berger |
officer: See Remarks |
7 DEERPARK DRIVE, STE K, MONMOUTH JUNCTION NJ 08852 |
| Thomas Bocchino |
officer: Chief Financial Officer |
C/O CYTOSORBENTS CORP., 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852 |
CytoSorbents (CytoSorbents) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CTSO has been successfully added to your 